You are here:Home-Research Areas-Neurological Disease-Anxiety

Request The Product List ofAnxiety Anxiety

Cat. No. Product Name CAS No. Information
PC-36103

Trigriluzole

1926203-09-9 Trigriluzole (BHV-4157) is a novel glutamate modulator for the treatment of mild-to-moderate Alzheimer’s disease (AD); Trigriluzole is a third-generation prodrug and new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. Trigriluzole has a wide range of pharmacological actions, including interactions with several types of ion channels, cellular signaling mechanisms and facilitation of glutamate reuptake. Some potential targets related to trigriluzole’s mechanism of action include (1) reducing presynaptic glutamate release through actions at the voltage-gated ion channels, (2) facilitating glutamate uptake via EAATs located on glial cells, (3) enhancing transmission through synaptic AMPA receptors, (4) altering GABAergic neurotransmission, and (5) effecting neurotrophic agents such as BDNF.

Anxiety

Phase 3 Clinical

PC-43382

WAY-100635 maleate

634908-75-1 WAY-100635 is a potent and selective 5-HT1A receptor antagonist; also acts as potent full agonist at the D4 receptor; completely prevents not only the hyperpolarization, with an IC50 of 1.3 nM, but also the decrease in membrane input resistance produced by 5-HT and 5-carboxamidotryptamine with IC50 of 22.5 μM and 50 nM, respectively.

Anxiety

Phase 1 Discontinued

PC-62769

TPA023

252977-51-8 TPA023 is a potent, α2/α3 subtype-selective, and oral GABAA receptor agonist with Kd of 0.92, 1.05 and 0.58 nM for α1-, α2-, α3-, and α5-containing human receptors; shows much lower (50- to 2000-fold) affinities for α4 and α6 subtypes (Ki= 60 and 418 nM, respectively); demonstrates anxiolytic-like efficacy and anticonvulsant activity in mouse pentylenetetrazole seizure model.

Anxiety

Discontinued

PC-62765

AZD6280

942436-93-3 AZD6280 is a potent, α2/3 functionally selective, partial GABAA receptor modulator with pKi of 7.7; exerts neutral antagonism at the α1-subunit and partial efficacy at the α2,3-subunits over the α5-subunit, shows potential for the treatment of anxiety disorders.

Anxiety

Phase 1 Discontinued

PC-62760

SB 206553

1197334-04-5 SB 206553 is a potent and selective 5-HT2B/5-HT2C receptor antagonist with pA2 of 8.89 for rat 5-HT2B, pKi of 7.92 for human 5-HT2C, displays >80-fold selectivity over other 5-HT receptor subtypes; exhibits anxiolytic-like properties both in vitro and in vivo.

Anxiety

Discontinued

PC-62533

SSR 411298

666860-59-9 SSR411298 is a highly selective, brain penetrant and orally-active inhibitor of FAAH with IC50 of 62.5 nM (mouse brain FAAH); potently increases hippocampal levels of AEA, OEA and PEA in mice, produces robust antidepressant-like activity in the rat forced-swimming test and in the mouse chronic mild stress models.

Anxiety

Phase 1 Clinical

PC-62090

AZD-7325

942437-37-8 AZD-7325 is a potent, α2/3 functionally selective, partial GABAA receptor modulator with pKi of 9.51; exerts neutral antagonism at the α1-subunit and partial efficacy at the α2,3-subunits over the α5-subunit; AZD7325 is expected to reduce the risk for the benzodiazepine like side effects, such as sedation and cognitive effects, and shows potential for the treatment of anxiety.

Anxiety

Phase 1 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com